- Home
- MEGL vs BDRX Comparison
MEGL vs BDRX Comparison
Compare MEGL & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- BDRX
- Stock Information
- Founded
- MEGL 2016
- BDRX 2000
- Country
- MEGL Hong Kong
- BDRX United Kingdom
- Employees
- MEGL N/A
- BDRX N/A
- Industry
- MEGL Finance: Consumer Services
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- BDRX Health Care
- Exchange
- MEGL Nasdaq
- BDRX Nasdaq
- Market Cap
- MEGL 5.7M
- BDRX 5.8M
- IPO Year
- MEGL 2022
- BDRX N/A
- Fundamental
- Price
- MEGL $1.60
- BDRX $0.90
- Analyst Decision
- MEGL
- BDRX
- Analyst Count
- MEGL 0
- BDRX 0
- Target Price
- MEGL N/A
- BDRX N/A
- AVG Volume (30 Days)
- MEGL 3.1M
- BDRX 3.2M
- Earning Date
- MEGL 07-07-2025
- BDRX 04-11-2025
- Dividend Yield
- MEGL N/A
- BDRX N/A
- EPS Growth
- MEGL N/A
- BDRX N/A
- EPS
- MEGL N/A
- BDRX N/A
- Revenue
- MEGL $1,645,862.00
- BDRX N/A
- Revenue This Year
- MEGL N/A
- BDRX N/A
- Revenue Next Year
- MEGL N/A
- BDRX N/A
- P/E Ratio
- MEGL N/A
- BDRX N/A
- Revenue Growth
- MEGL N/A
- BDRX N/A
- 52 Week Low
- MEGL $1.02
- BDRX $0.78
- 52 Week High
- MEGL $5.52
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- MEGL 52.58
- BDRX 39.25
- Support Level
- MEGL $1.46
- BDRX $0.85
- Resistance Level
- MEGL $1.85
- BDRX $0.97
- Average True Range (ATR)
- MEGL 0.25
- BDRX 0.11
- MACD
- MEGL -0.01
- BDRX -0.00
- Stochastic Oscillator
- MEGL 26.64
- BDRX 28.24
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.